Stockreport

Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF See our latest analysis for Beam Therapeutics. The recent FDA alignment on BEAM-302 and the extended cash runway appear to be in focus for traders, with a 1-day share [Read more]